AAAAAA
Results: 1-25/33
Authors:
Talbot, JN
Haioun, C
Rain, JD
Meignan, M
Wioland, M
Misset, JL
Grahek, D
Kerrou, K
Montravers, F
Citation: Jn. Talbot et al., [18F]-FDG positron imaging in clinical management of lymphoma patients, CR R ONC H, 38(3), 2001, pp. 193-221
Authors:
Misset, JL
Vennin, P
Chollet, P
Pouillart, P
Laplaige, P
Frobert, JL
Castera, D
Fabro, M
Langlois, D
Cortesi, E
Lucas, V
Gamelin, E
Laadem, A
Otero, J
Citation: Jl. Misset et al., Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients, ANN ONCOL, 12(10), 2001, pp. 1411-1415
Authors:
Delaloge, S
Yovine, A
Taamma, A
Riofrio, M
Brain, E
Raymond, E
Cottu, P
Goldwasser, F
Jimeno, J
Misset, JL
Marty, M
Cvitkovic, E
Citation: S. Delaloge et al., Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity, J CL ONCOL, 19(5), 2001, pp. 1248-1255
Authors:
Taamma, A
Misset, JL
Riofrio, M
Guzman, C
Brain, E
Lazaro, LL
Rosing, H
Jimeno, JM
Cvitkovic, E
Citation: A. Taamma et al., Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J CL ONCOL, 19(5), 2001, pp. 1256-1265
Authors:
Levi, F
Giacchetti, S
Zidani, R
Brezault-Bonnet, C
Tigaud, JM
Goldwasser, F
Misset, JL
Citation: F. Levi et al., Chronotherapy of colorectal cancer metastases, HEP-GASTRO, 48(38), 2001, pp. 320-322
Authors:
Goldwasser, F
Misset, JL
Citation: F. Goldwasser et Jl. Misset, Clinical use of oxaliplatin in solid tumors, B CANCER, 88, 2001, pp. S40-S44
Authors:
Tubiana-Hulin, M
Beuzeboc, P
Mauriac, L
Barbet, N
Frenay, M
Monnier, A
Pion, JM
Switsers, O
Misset, JL
Assadourian, S
Bessa, E
Citation: M. Tubiana-hulin et al., Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases, B CANCER, 88(7), 2001, pp. 701-707
Authors:
Mormont, MC
Waterhouse, J
Bleuzen, P
Giacchetti, S
Jami, A
Bogdan, A
Lellouch, J
Misset, JL
Touitou, Y
Levi, F
Citation: Mc. Mormont et al., Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status, CLIN CANC R, 6(8), 2000, pp. 3038-3045
Authors:
van Kesteren, C
Cvitkovic, E
Taamma, A
Lopez-Lazaro, L
Jimeno, JM
Guzman, C
Mathot, RAA
Schellens, JHM
Misset, JL
Brain, E
Hillebrand, MJX
Rosing, H
Beijnen, JH
Citation: C. Van Kesteren et al., Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study, CLIN CANC R, 6(12), 2000, pp. 4725-4732
Authors:
Misset, JL
Bleiberg, H
Sutherland, W
Bekradda, M
Cvitkovic, E
Citation: Jl. Misset et al., Oxaliplatin clinical activity: a review, CR R ONC H, 35(2), 2000, pp. 75-93
Authors:
Gornet, JM
Azoulay, D
Levi, F
Yovine, A
Misset, JL
Goldwasser, F
Citation: Jm. Gornet et al., Dramatic tumor response of bulky liver metastases following treatment withCPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient, ANTI-CANC D, 11(4), 2000, pp. 263-268
Authors:
Goldwasser, F
Gross-Goupil, M
Tigaud, JM
Di Palma, M
Marceau-Suissa, J
Wasserman, E
Yovine, A
Misset, JL
Cvitkovic, E
Citation: F. Goldwasser et al., Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients, ANN ONCOL, 11(11), 2000, pp. 1463-1470
Authors:
Alexandre, J
Bleuzen, P
Bonneterre, J
Sutherland, W
Misset, JL
Guastalla, JP
Viens, P
Faivre, S
Chahine, A
Spielman, M
Bensmaine, A
Marty, M
Mahjoubi, M
Cvitkovic, E
Citation: J. Alexandre et al., Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients, J CL ONCOL, 18(3), 2000, pp. 562-573
Authors:
Giacchetti, S
Perpoint, B
Zidani, R
Le Bail, N
Faggiuolo, R
Focan, C
Chollet, P
Llory, JF
Letourneau, Y
Coudert, B
Bertheaut-Cvitkovic, F
Larregain-Fournier, D
Le Rol, A
Walter, S
Adam, R
Misset, JL
Levi, F
Citation: S. Giacchetti et al., Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer, J CL ONCOL, 18(1), 2000, pp. 136-147
Authors:
Massari, C
Brienza, S
Rotarski, M
Gastiaburu, J
Misset, JL
Cupissol, D
Alafaci, E
Dutertre-Catella, H
Bastian, G
Citation: C. Massari et al., Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function, CANC CHEMOT, 45(2), 2000, pp. 157-164
Authors:
Delaloge, S
Laadem, A
Taamma, A
Chouaki, N
Cvitkovic, E
Pautier, P
Misset, JL
Lhomme, C
Citation: S. Delaloge et al., Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer, AM J CL ONC, 23(6), 2000, pp. 569-574
Authors:
Emile, JF
Di Palma, M
Musset, M
Sebagh, M
Auriault, ML
Misset, JL
Reynes, M
Citation: Jf. Emile et al., Impact of pathology slide review on clinical practice in an oncology center, ANN PATHOL, 20(4), 2000, pp. 304-307
Authors:
Misset, JL
Levi, F
Citation: Jl. Misset et F. Levi, Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies, SEMIN ONCOL, 27(5), 2000, pp. 78-82
Authors:
Bonneterre, J
Spielman, M
Guastalla, JP
Marty, M
Viens, P
Chollet, P
Roche, H
Fumoleau, P
Mauriac, L
Bourgeois, H
Namer, M
Bergerat, JP
Misset, JL
Trandafir, L
Mahjoubi, M
Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439
Authors:
Focan, C
Levi, F
Kreutz, F
Focan-Henrard, D
Lobelle, JP
Adam, R
Dallemagne, B
Jehaes, C
Markiewicz, S
Weerts, J
Bismuth, H
Jasmin, C
Misset, JL
Citation: C. Focan et al., Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion, ANTI-CANC D, 10(4), 1999, pp. 385-392
Authors:
Goldwasser, F
Buthaud, X
Gross, M
Bleuzen, P
Cvitkovic, E
Voinea, A
Jasmin, C
Romain, D
Misset, JL
Citation: F. Goldwasser et al., Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients, ANTI-CANC D, 10(3), 1999, pp. 263-265
Authors:
Goldwasser, F
Bozec, L
Zeghari-Squalli, N
Misset, JL
Citation: F. Goldwasser et al., Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line, ANTI-CANC D, 10(2), 1999, pp. 195-201
Authors:
Armand, JP
Cunningham, D
van Cutsem, E
Misset, JL
Kohne, CH
Citation: Jp. Armand et al., Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies, ANTI-CANC D, 10, 1999, pp. S5-S12
Authors:
Giacchetti, S
Itzhaki, M
Gruia, G
Adam, R
Zidani, R
Kunstlinger, F
Brienza, S
Alafaci, E
Bertheault-Cvitkovic, F
Jasmin, C
Reynes, M
Bismuth, H
Misset, JL
Levi, F
Citation: S. Giacchetti et al., Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery, ANN ONCOL, 10(6), 1999, pp. 663-669
Authors:
Misset, JL
Dieras, V
Gruia, G
Bourgeois, H
Cvitkovic, E
Kalla, S
Bozec, L
Beuzeboc, P
Jasmin, C
Aussel, JP
Riva, A
Azli, N
Pouillart, P
Citation: Jl. Misset et al., Dose-finding study of docetaxel and doxorubicin in first-line treatment ofpatients with metastatic breast cancer, ANN ONCOL, 10(5), 1999, pp. 553-560